Welcome!

News Feed Item

Investigation Report on China Montelukast Market

DUBLIN, March 25, 2014 /PRNewswire/ --

Research  and  Markets (http://www.researchandmarkets.com/research/rq8jml/investigation) has announced the addition of the "Investigation Report on China Montelukast Market" report to their offering.
     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

There are over 30 million people suffering from seasonal asthma of different levels worldwide, and the situation is worse in deeply contaminated countries and regions with high tobacco consumption. Asthma and allergic rhinitis are both very common diseases in the world today. As the atmosphere becomes more seriously contaminated, incidence of these diseases increases year by year.

Montelukast, developed by MSD Co., Ltd., is widely used in curing allergic rhinitis and asthma. Montelukast is a CysLT1 antagonist that blocks the action of leukotriene D4 on the cysteinyl leukotriene receptor CysLT1 in the lungs and bronchial tubes by binding to it. This reduces the broncho-constriction otherwise caused by the leukotriene and results in less inflammation.

In 1998, montelukast sodium tablets (10mg) and chewable tablets (5mg) were approved by FDA to the market with the trade name ""Singulair"". In 2000 and 2002, montelukast chewable tablets (4mg) and montelukast granules (4mg) were approved to the market in turn. They are mainly used in prevention and long-term treatment of asthma of adult and children aged two and above.

Patent of Singulair in U.S. expired on August 3, 2012. Hereafter, FDA approved over 10 manufacturers' applications for their generic drugs to the market. Among them, Teva Pharmaceutical Industries Limited launched tablets, chewable tablets and oral granules while Dr. Reddy's Laboratories Ltd. launched tablets and chewable tablets. In 2012, due to the generic drug intrusion, sales revenue of Singulair produced by MSD Co., Ltd. dropped to USD 3,853 million, decreased by 30%.

In 1999, montelukast chewable tablets (5mg) and tablets (10mg) produced by MSD Co., Ltd. were allowed to enter China with the trade name ""Singulair"". Hereafter, montelukast chewable tablets (4mg) and granules (4mg) were permitted into Chinese market sequentially. Generic montelukast tablets (10mg) and chewable tablets (5mg) produced by Sichuan Otsuka Pharmaceutical Co., Ltd. were approved to the market in 2006 with the trade name ""Bai Sanping"". Mudanjiang Hengyuan Pharmaceutical Co., Ltd. was the first manufacturer that acquired approval of montelukast sodium raw material production in 2006. In 2008, Lunan Better Pharmaceutical Co., LTD. was given the approval of montelukast tablets (10mg) and chewable tablets (5mg). In addition, many drug manufacturers such as YZJ Group and Beijing Winsunny Pharmaceutical Company Limited have applied for generic drugs production.


Key  Topics  Covered:

1 Relevant Concepts of Montelukast

2 Market Overview of Montelukast in China

3 Investigation on Sales Value of Montelukast in China, 2009-2013

4 Investigation on Market Share of Major Montelukast Manufacturers in China, 2009-2013

5 Investigation on Market Size of Montelukast by Dosage Form in China, 2009-2013

6 Reference Price of Montelukast Produced by Different Enterprises in China Hospital Market, 2013

7 Analysis on Major Montelukast Manufacturers in China, 2009-2013

8 Prospect of China Montelukast Market, 2014-2018


Companies  Mentioned:

  • MSD (UK)
  • Sichuan Xicheng Otsuka Pharmaceutical Co., Ltd.
  • Lunan Better Pharmaceutical Co., Ltd.
  • Merck & Co., Inc. (USA)


For more information visit http://www.researchandmarkets.com/research/rq8jml/investigation


Media  Contact: Laura Wood , +353-1-481-1716, [email protected]


SOURCE Research and Markets

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Evan Kirstel is an internationally recognized thought leader and social media influencer in IoT (#1 in 2017), Cloud, Data Security (2016), Health Tech (#9 in 2017), Digital Health (#6 in 2016), B2B Marketing (#5 in 2015), AI, Smart Home, Digital (2017), IIoT (#1 in 2017) and Telecom/Wireless/5G. His connections are a "Who's Who" in these technologies, He is in the top 10 most mentioned/re-tweeted by CMOs and CIOs (2016) and have been recently named 5th most influential B2B marketeer in the US. H...
Gemini is Yahoo’s native and search advertising platform. To ensure the quality of a complex distributed system that spans multiple products and components and across various desktop websites and mobile app and web experiences – both Yahoo owned and operated and third-party syndication (supply), with complex interaction with more than a billion users and numerous advertisers globally (demand) – it becomes imperative to automate a set of end-to-end tests 24x7 to detect bugs and regression. In th...
"With Digital Experience Monitoring what used to be a simple visit to a web page has exploded into app on phones, data from social media feeds, competitive benchmarking - these are all components that are only available because of some type of digital asset," explained Leo Vasiliou, Director of Web Performance Engineering at Catchpoint Systems, in this SYS-CON.tv interview at DevOps Summit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"Venafi has a platform that allows you to manage, centralize and automate the complete life cycle of keys and certificates within the organization," explained Gina Osmond, Sr. Field Marketing Manager at Venafi, in this SYS-CON.tv interview at DevOps at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Michael Maximilien, better known as max or Dr. Max, is a computer scientist with IBM. At IBM Research Triangle Park, he was a principal engineer for the worldwide industry point-of-sale standard: JavaPOS. At IBM Research, some highlights include pioneering research on semantic Web services, mashups, and cloud computing, and platform-as-a-service. He joined the IBM Cloud Labs in 2014 and works closely with Pivotal Inc., to help make the Cloud Found the best PaaS.
Creating replica copies to tolerate a certain number of failures is easy, but very expensive at cloud-scale. Conventional RAID has lower overhead, but it is limited in the number of failures it can tolerate. And the management is like herding cats (overseeing capacity, rebuilds, migrations, and degraded performance). In his general session at 18th Cloud Expo, Scott Cleland, Senior Director of Product Marketing for the HGST Cloud Infrastructure Business Unit, discussed how a new approach is neces...
"This week we're really focusing on scalability, asset preservation and how do you back up to the cloud and in the cloud with object storage, which is really a new way of attacking dealing with your file, your blocked data, where you put it and how you access it," stated Jeff Greenwald, Senior Director of Market Development at HGST, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Cloud-enabled transformation has evolved from cost saving measure to business innovation strategy -- one that combines the cloud with cognitive capabilities to drive market disruption. Learn how you can achieve the insight and agility you need to gain a competitive advantage. Industry-acclaimed CTO and cloud expert, Shankar Kalyana presents. Only the most exceptional IBMers are appointed with the rare distinction of IBM Fellow, the highest technical honor in the company. Shankar has also receive...
"Evatronix provides design services to companies that need to integrate the IoT technology in their products but they don't necessarily have the expertise, knowledge and design team to do so," explained Adam Morawiec, VP of Business Development at Evatronix, in this SYS-CON.tv interview at @ThingsExpo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Business professionals no longer wonder if they'll migrate to the cloud; it's now a matter of when. The cloud environment has proved to be a major force in transitioning to an agile business model that enables quick decisions and fast implementation that solidify customer relationships. And when the cloud is combined with the power of cognitive computing, it drives innovation and transformation that achieves astounding competitive advantage.
"We work around really protecting the confidentiality of information, and by doing so we've developed implementations of encryption through a patented process that is known as superencipherment," explained Richard Blech, CEO of Secure Channels Inc., in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
"I focus on what we are calling CAST Highlight, which is our SaaS application portfolio analysis tool. It is an extremely lightweight tool that can integrate with pretty much any build process right now," explained Andrew Siegmund, Application Migration Specialist for CAST, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
The Founder of NostaLab and a member of the Google Health Advisory Board, John is a unique combination of strategic thinker, marketer and entrepreneur. His career was built on the "science of advertising" combining strategy, creativity and marketing for industry-leading results. Combined with his ability to communicate complicated scientific concepts in a way that consumers and scientists alike can appreciate, John is a sought-after speaker for conferences on the forefront of healthcare science,...
"Software-defined storage is a big problem in this industry because so many people have different definitions as they see fit to use it," stated Peter McCallum, VP of Datacenter Solutions at FalconStor Software, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
"Our strategy is to focus on the hyperscale providers - AWS, Azure, and Google. Over the last year we saw that a lot of developers need to learn how to do their job in the cloud and we see this DevOps movement that we are catering to with our content," stated Alessandro Fasan, Head of Global Sales at Cloud Academy, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.